Clinical trials: Stage IVA Squamous Cell Carcinoma of the Larynx
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma
Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
This phase II trial studies the effect of cemiplimab in combination with low-dose paclitaxel and carboplatin in treating patients with squamous cell carcinoma of the head and neck that has come back (recurrent) or spread to other…
- Conditions
- Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma
- Trial name
- NCT04862650
- Testing
- Carboplatin, Cemiplimab, Paclitaxel
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Marcelo Bonomi
Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Hypopharynx
Paclitaxel and Carboplatin Before Radiation Therapy With Paclitaxel in Treating HPV-Positive Patients With Stage III-IV Oropharynx, Hypopharynx, or Larynx Cancer
This phase II trial studies how well paclitaxel and carboplatin before radiation therapy with paclitaxel works in treating human papillomavirus (HPV)-positive patients with stage III-IV oropharynx, hypopharynx, or larynx cancer.
- Conditions
- Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Oropharynx
- Trial name
- NCT02048020
- Testing
- paclitaxel, carboplatin, intensity-modulated radiation therapy
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
This phase II trial is studying how well SB-715992 works in treating patients with recurrent or metastatic head and neck cancer.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT00095628
- Testing
- ispinesib, laboratory biomarker analysis, pharmacological study
- Where
- Canada
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer
Studying Biomarkers in Samples From Patients With Recurrent or Metastatic Head and Neck Cancer Treated on E1302 Trial
RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01619618
- Testing
- mutation analysis, polymerase chain reaction, polymorphism analysis
- Volunteers
- 183 people
- Sponsor
- Eastern Cooperative Oncology Group
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
This phase II trial is studying the how well saracatinib works in treating patients with metastatic or recurrent head and neck cancer.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx
- Trial name
- NCT00513435
- Testing
- saracatinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Mucositis, Oral Complications
Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy
This randomized pilot clinical trial studies whether acetylcysteine oral rinse will lessen saliva thickness and painful mouth sores in patients with head and neck cancer undergoing radiation therapy.
- Conditions
- Mucositis, Oral Complications, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip
- Trial name
- NCT02123511
- Testing
- acetylcysteine, quality-of-life assessment, questionnaire administration
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- Mayo Clinic
Recurrent Colon Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma
Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer
This phase I trial studies the side effects and the best dose of lenalidomide when given together with cetuximab in treating patients with colorectal cancer or head and neck cancer that has spread to other places in the body and…
- Conditions
- Recurrent Colon Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma
- Trial name
- ADCC (NCT01254617)
- Testing
- Cetuximab, Laboratory Biomarker Analysis, Lenalidomide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer
Biomarkers in Patients With Metastatic or Recurrent Head and Neck Cancer Treated With Cisplatin and Cetuximab on ECOG-E5397
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors predict how well patients will respond to treatment.
- Trial name
- NCT01466244
- Testing
- cetuximab, cisplatin, gene expression analysis
- Volunteers
- 42 people
- Sponsor
- Eastern Cooperative Oncology Group
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Salivary Gland Squamous Cell Carcinoma
Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer.
This randomized phase I/II trial studies the side effects and best way to give lyophilized black raspberries in preventing oral cancer in high-risk patients previously diagnosed with stage I-IV or in situ head and neck cancer.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Salivary Gland Squamous Cell Carcinoma, Stage 0 Hypopharyngeal Cancer, Stage 0 Laryngeal Cancer
- Trial name
- NCT01469429
- Testing
- laboratory biomarker analysis, questionnaire administration, chemoprevention
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
PET/CT Assessment of Radiation-Induced Vascular Complications in Head and Neck Cancer
This early phase I trial compares sodium fluoride F-18 (F-18 NaF) positron emission tomography (PET)/computed tomography (CT) to the standard of care imaging scan (and fludeoxyglucose F-18 [F-18 FDG] PET/CT) for assessing the…
- Conditions
- Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT06914999
- Testing
- Computed Tomography, Fludeoxyglucose F-18, Intensity-Modulated Proton Therapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Emory University
Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
This phase II trial compares the effectiveness of cemiplimab with CDX-1140 to cemiplimab without CDX-1140 prior to surgery in treating patients with stage III-IV head and neck cancer.
- Conditions
- Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Nasal Cavity Squamous Cell Carcinoma
- Trial name
- NCT06980038
- Testing
- Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Biopsy Procedure, Biospecimen Collection
- Where
- 12 sites in United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7
Onalespib in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin
This phase I trial studies the side effects and best dose of onalespib when given together with intensity-modulated radiation therapy (IMRT) and cisplatin in treating patients with squamous cell carcinoma of the head and neck…
- Conditions
- Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7
- Trial name
- NCT02381535
- Testing
- Cisplatin, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis
- Where
- 2 sites in United States, Canada
- Volunteers
- 2 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma
Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
This randomized phase II trial studies how well cisplatin with or without WEE1 inhibitor MK-1775 works in treating patients with head and neck cancer that has come back or has spread to other parts of the body.
- Conditions
- Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma
- Trial name
- NCT02196168
- Testing
- Cisplatin, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 3 sites in Canada
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer, Oral Complications of Radiation Therapy
CD2 Lozenges in Preventing Acute Oral Mucositis in Patients With Head and Neck Cancer Receiving Radiotherapy and Chemotherapy
RATIONALE: Lactobacillus bevis CD2 lozenge may help prevent symptoms of mucositis, or mouth sores, in patients receiving radiation therapy and chemotherapy.
- Conditions
- Head and Neck Cancer, Oral Complications of Radiation Therapy, Pain, Weight Changes
- Trial name
- NCT01545687
- Testing
- Lactobacillus brevis CD2 lozenge
- Sponsor
- Alliance for Clinical Trials in Oncology
Metastatic Squamous Cell Carcinoma of the Hypopharynx, Metastatic Squamous Cell Carcinoma of the Larynx
Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
This randomized phase II trial studies how well combination chemotherapy with or without erlotinib hydrochloride works in treating patients with squamous cell carcinoma of the head and neck that has spread to other parts of the…
- Conditions
- Metastatic Squamous Cell Carcinoma of the Hypopharynx, Metastatic Squamous Cell Carcinoma of the Larynx, Metastatic Squamous Cell Carcinoma of the Oral Cavity, Metastatic Squamous Cell Carcinoma of the Oropharynx
- Trial name
- NCT01064479
- Testing
- Carboplatin, Cisplatin, Docetaxel
- Where
- 5 sites in United States
- Volunteers
- 123 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Salivary Gland Squamous Cell Carcinoma
Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung Cancer
This pilot research trial studies circulating tumor deoxyribonucleic acid (DNA) in predicting outcomes in patients with stage IV head and neck cancer or stage III-IV non-small cell lung cancer.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Salivary Gland Squamous Cell Carcinoma, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
- Trial name
- NCT02245100
- Testing
- Cytology specimen, Laboratory biomarker analysis
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7
Cisplatin, Intensity-Modulated Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma
This phase I trial studies the side effects and best dose of pembrolizumab when given together with cisplatin and intensity-modulated radiation therapy, in treating patients with stage III-IV squamous cell carcinoma of the head…
- Conditions
- Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7
- Trial name
- NCT02775812
- Testing
- Cisplatin, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis
- Where
- 69 sites in United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx
Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
This phase II trial studies how well lapatinib ditosylate works in treating patients with metastatic or recurrent head and neck cancer.
- Conditions
- Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity
- Trial name
- NCT00114283
- Testing
- lapatinib ditosylate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT00939627
- Testing
- cetuximab, sorafenib tosylate, laboratory biomarker analysis
- Where
- 8 sites in United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
This phase I/II trial studies the side effects and the best dose of sorafenib tosylate and docetaxel when given together with cisplatin and to see how well they work in treating patients with recurrent or metastatic squamous cell…
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT02035527
- Testing
- sorafenib tosylate, cisplatin, docetaxel
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Ohio State University Comprehensive Cancer Center